Skip to main content
Terug
RKAGY logo

RHON-KLINIKUM AG Unsponsored ADR

Datakwaliteit: 100%
Overbought
RKAGY
OTC Healthcare Medical - Care Facilities
€ 8,16
€ 0,00 (0,00%)
Marktkapitalisatie: 1,09B
Dagbereik
€ 8,16 € 8,16
52-Weeksbereik
€ 6,05 € 9,07
Volume
100
50D / 200D Gem.
€ 7,95 / € 7,56
Vorige Slotkoers
€ 8,16

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 25,2 0,3
P/B 0,8 2,9
ROE % 3,4 3,7
Net Margin % 2,7 3,8
Rev Growth 5Y % 4,1 10,0
D/E 0,1 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2026 € 0,00
€ 0,00 – € 0,00
 1,5 B 0

Belangrijkste Punten

Revenue grew 4,07% annually over 5 years — modest growth
ROE of 3,40% is below average
Debt/Equity of 0,12 — conservative balance sheet
Generating 57,20M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 4,92%
Cash machine — converts 131,95% of earnings into free cash flow

Groei

Revenue Growth (5Y)
4,07%
Revenue (1Y)8,99%
Earnings (1Y)11,98%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
3,40%
ROIC2,50%
Net Margin2,72%
Op. Margin3,02%

Veiligheid

Debt / Equity
0,12
Current Ratio2,23
Interest Coverage14,16

Waardering

P/E Ratio
25,20
P/B Ratio0,84
EV/EBITDA19,98
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8,99% Revenue Growth (3Y) 5,04%
Earnings Growth (1Y) 11,98% Earnings Growth (3Y) 31,31%
Revenue Growth (5Y) 4,07% Earnings Growth (5Y) 133,79%
Profitability
Revenue (TTM) 1,60B Net Income (TTM) 43,35M
ROE 3,40% ROA 2,34%
Gross Margin 10,77% Operating Margin 3,02%
Net Margin 2,72% Free Cash Flow (TTM) 57,20M
ROIC 2,50% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,12 Current Ratio 2,23
Interest Coverage 14,16 Dividend Yield 0,00%
Valuation
P/E Ratio 25,20 P/B Ratio 0,84
P/S Ratio 0,68 PEG Ratio 1,12
EV/EBITDA 19,98 Dividend Yield 0,00%
Market Cap 1,09B Enterprise Value 962,17M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1,60B 1,46B 1,45B 1,59B 1,36B
Net Income 43,35M 38,71M 25,14M 28,30M 1,45M
EPS (Diluted) 0,34 0,29 0,19 0,21 0,01
Gross Profit 171,82M 148,81M 999,52M 182,63M 937,72M
Operating Income 48,15M 40,40M 36,11M 30,52M 10,60M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 1,86B 1,77B 1,70B 1,67B 1,63B
Total Liabilities 530,51M 490,30M 453,51M 440,82M 439,45M
Shareholders' Equity 1,30B 1,25B 1,22B 1,20B 1,17B
Total Debt 149,60M 149,90M 158,20M 159,76M 160,60M
Cash & Equivalents 279,86M 206,04M 77,33M 126,32M 90,96M
Current Assets 904,11M 789,21M 688,61M 611,08M 566,43M
Current Liabilities 404,85M 335,47M 291,08M 273,31M 273,38M

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#980 of 1052
20
Custom Deep Value Investing (Seth Klarman)
#669 of 825
27

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026